| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c54be40fa7f9e3e45bb7b6d56a9bea9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41f348171d4db3451c79fee043df6cc0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10c162e772379c5c39d53c7a9783140b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C39-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C35-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 |
| filingDate |
2018-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea345b88240e4c02a144ceae4caf0e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d932288eabf9104f87b3a15eb0e1893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea2f1171d6c3db595198367ce9546277 |
| publicationDate |
2020-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3601204-A1 |
| titleOfInvention |
Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation |
| abstract |
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and substituted (4'-hydroxylphenyl)cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERĪ²). The disclosed compounds may be formulated as pharmaceutical compositions and administered for treating diseases associated with ER activity, such as neurological, psychiatric, and/or cell proliferative diseases and disorders as well as for enhancing memory consolidation in subjects in need thereof. |
| priorityDate |
2017-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |